Compare NTRA & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | IR |
|---|---|---|
| Founded | 2003 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 33.8B |
| IPO Year | 2015 | 2017 |
| Metric | NTRA | IR |
|---|---|---|
| Price | $187.50 | $81.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $259.07 | $99.86 |
| AVG Volume (30 Days) | 1.0M | ★ 3.1M |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 1.45 |
| Revenue | $210,939,000.00 | ★ $2,375,400,000.00 |
| Revenue This Year | $16.65 | $7.23 |
| Revenue Next Year | $19.22 | $4.80 |
| P/E Ratio | ★ N/A | $55.97 |
| Revenue Growth | N/A | ★ 22.48 |
| 52 Week Low | $125.38 | $65.61 |
| 52 Week High | $256.36 | $100.96 |
| Indicator | NTRA | IR |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 30.64 |
| Support Level | $182.20 | $78.21 |
| Resistance Level | $251.09 | $84.66 |
| Average True Range (ATR) | 8.09 | 2.42 |
| MACD | -1.01 | -1.59 |
| Stochastic Oscillator | 7.21 | 13.95 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.